Ian A Cliffe

List of Publications by Year
in descending order

44 papers	2,782 citations	361296 20 h-index	276775 41 g-index
46 all docs	46 docs citations	46 times ranked	2005 citing authors

#	Article	IF	Citations
1	Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2313-2318.	1.0	14
2	Synthesis and evaluation of 4,5-dihydro-5-methylisoxazolin-5-carboxamide derivatives as VLA-4 antagonists. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1482-1485.	1.0	10
3	RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy. European Journal of Pharmacology, 2013, 711, 19-26.	1.7	7
4	Efficient and Selective Demethylation of Heteroaryl Methyl Ethers in the Presence of Aryl Methyl Ethers. Synthetic Communications, 2011, 41, 1852-1857.	1.1	8
5	Pharmacodynamic and pharmacokinetic profile of RBx 343E48F0: A novel, long acting muscarinic receptor antagonist. European Journal of Pharmacology, 2011, 658, 219-228.	1.7	5
6	Synthesis and in vitro activity of novel 1,2,4-triazolo[4,3-a]pyrimidine oxazolidinone antibacterial agents. Part II. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5266-5269.	1.0	12
7	Synthesis and in vitro activity of novel 1,2,4-triazolo[4,3-a]pyrimidine oxazolidinone antibacterial agents. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2887-2889.	1.0	41
8	UDP-N-acetylglucosamine enolpyruvyl transferase from Pseudomonas aeruginosa. World Journal of Microbiology and Biotechnology, 2010, 26, 1623-1629.	1.7	4
9	Synthesis and biological activity of N-substituted aminocarbonyl-1,3-dioxolanes as VLA-4 antagonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5514-5520.	1.0	7
10	Assessment of the putative binding conformation of a pyrazolopyridine class of inhibitors of MAPKAPK2 using computational studies. European Journal of Medicinal Chemistry, 2010, 45, 98-105.	2.6	5
11	Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2924-2929.	1.0	60
12	Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2916-2919.	1.0	40
13	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2920-2923.	1.0	28
14	Progress in the development of small molecule inhibitors of insulin-like growth factor-1 receptor kinase. Expert Opinion on Therapeutic Patents, 2007, 17, 25-35.	2.4	9
15	Synthesis and antibacterial activity of potent heterocyclic oxazolidinones and the identification of RBx 8700. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6714-6719.	1.0	10
16	Synthesis and optimization of novel and selective muscarinic M3 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5256-5260.	1.0	5
17	Peptidomimetic GnRH receptor antagonists for the treatment of reproductive and proliferative diseases. Expert Opinion on Therapeutic Patents, 2006, 16, 733-751.	2.4	6
18	Pyrrolo(iso)quinoline derivatives as 5-HT2C receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 677-680.	1.0	26

#	Article	IF	Citations
19	Synthesis and biological evaluation of novel hexahydro-pyrido[3â€²,2â€²:4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT2C receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1207-1211.	1.0	39
20	Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3604-3608.	1.0	22
21	Indoline derivatives as 5-HT 2C receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2367-2370.	1.0	45
22	5-HT_{2C} Receptor Agonists for the Treatment of Obesity. Biological and Chemical Adventures. Chimia, 2004, 58, 613-620.	0.3	18
23	A retrospect on the discovery of way-100635 and the prospect for improved 5-HT1A receptor PET radioligands. Nuclear Medicine and Biology, 2000, 27, 441-447.	0.3	42
24	Synthesis, Physicochemical Properties, Anticonvulsant Activities, and GABA-ergic and Voltage-sensitive Calcium Channel Receptor Affinities of Î±-SubstitutedN-Benzylamides of Î³-Hydroxybutyric Acid Part 4: Search for New Anticonvulsant Compounds. Archiv Der Pharmazie, 1999, 332, 167-174.	2.1	9
25	Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635. Brain Research, 1997, 745, 96-108.	1.1	259
26	Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methl-11C]WAY-100635, in monkey and human plasma by HPLC: Comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. Nuclear Medicine and Biology, 1996, 23, 627-634.	0.3	98
27	Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11C]WAY-100635. European Journal of Pharmacology, 1996, 301, R5-R7.	1.7	204
28	Visualization and characterization of 5-HT receptors and transporters in vivo and in man. Seminars in Neuroscience, 1995, 7, 421-431.	2.3	12
29	Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behavioural Brain Research, 1995, 73, 337-353.	1.2	461
30	A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. European Journal of Pharmacology, 1995, 281, 81-88.	1.7	537
31	First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635. European Journal of Pharmacology, 1995, 283, R1-R3.	1.7	103
32	Preclinical Development of a Radioligand for the Study of Central 5-HT1A Receptors with PET â€" [11C]Way-100635. , 1995, , 93-108.		1
33	Functions Containing an Iminocarbonyl Group and Any Elements Other Than a Halogen or Chalcogen. , 1995, , 639-675.		1
34	Evaluation of [O-methyl-3H]WAY-100635 as an in vivo radioligand for 5-HT1A receptors in rat brain. European Journal of Pharmacology, 1994, 271, 515-523.	1.7	69
35	WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. European Journal of Pharmacology, 1993, 237, 283-291.	1.7	208
36	(S)-N-tert-Butyl-3-(4-(2-methoxyphenyl)piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. Journal of Medicinal Chemistry, 1993, 36, 1509-1510.	2.9	86

#	Article	IF	Citations
37	Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents. Trends in Pharmacological Sciences, 1993, 14, 441-448.	4.0	176
38	Oral hypoglycemic agents. Pyrimido[1,2-a]indoles and related compounds. Journal of Medicinal Chemistry, 1992, 35, 1169-1175.	2.9	14
39	Azaheteroaromatic ethers as carbonyl bioisosteres. Synthesis and evaluation of a novel class of 5-HT3 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 1992, 2, 245-248.	1.0	0
40	7-amino-5,6,7,8-tetrahydroquinolines. Preparation from 5,6-dihydroquinoline and nitrogen nucleophiles. Tetrahedron Letters, 1991, 32, 6789-6792.	0.7	17
41	Synthesis of 2,2-Dialkyl-3-Halopropannitriles from 2,2-Dialkylethanenitrles and Dihalomethanes. Synthetic Communications, 1990, 20, 1757-1767.	1.1	6
42	Sterically Hindered Lithium Dialkylamides; A Novel Synthesis of Lithium Dialkylamides fromN-t-Alkyl-N-benzylideneamines and the Isolation of Highly Hindereds-Alkyl-t-alkylamines. Synthesis, 1985, 1985, 1138-1140.	1.2	13
43	The formation of complexes between aza derivatives of crown ethers and primary alkylammonium salts. Part 7. Chiral derivatives of aza crown ethers. Journal of the Chemical Society Perkin Transactions 1, 1984, , 1707.	0.9	25
44	Chiral diaza-18-crown-6 derivatives. Journal of the Chemical Society Chemical Communications, 1981, , 992.	2.0	19